Wikidata entity: Q425296
C₁₉H₂₁N₅O₄ (P274)
Quantities
| P4250 | defined daily dose | 5 |
| P2067 | mass | 383.159 |
| P3780 | active ingredient in | ... | Q47521838 (Minipress) | Minipress |
| P233 | canonical SMILES | String | COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC | ??? |
| P373 | Commons category | String | Prazosin | ??? |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P8026 | LiverTox likelihood score | ... | Q83284878 (Լյարդի ախտահարման հավանականության E կատեգորիա) | Լյարդի ախտահարման հավանականության E կատեգորիա |
| P2175 | medical condition treated | ... | Q41861 (arterial hypertension) | arterial hypertension |
| P2175 | medical condition treated | ... | Q202387 (post-traumatic stress disorder) | post-traumatic stress disorder |
| P2175 | medical condition treated | ... | Q1053824 (Raynaud disease) | Raynaud disease |
| P2175 | medical condition treated | ... | Q506659 (prostatic hypertrophy) | prostatic hypertrophy |
| P2175 | medical condition treated | ... | Q1366695 (urinary retention) | urinary retention |
| P129 | physically interacts with | ... | Q4734884 (Adrenoceptor alpha 1A) | Adrenoceptor alpha 1A |
| P129 | physically interacts with | ... | Q4734886 (Adrenoceptor alpha 1B) | Adrenoceptor alpha 1B |
| P129 | physically interacts with | ... | Q4734887 (Adrenoceptor alpha 1D) | Adrenoceptor alpha 1D |
| P129 | physically interacts with | ... | Q4734891 (Adrenoceptor alpha 2C) | Adrenoceptor alpha 2C |
| P129 | physically interacts with | ... | Q4734892 (Adrenoceptor alpha 2A) | Adrenoceptor alpha 2A |
| P129 | physically interacts with | ... | Q21141045 (Adrenoceptor alpha 2B) | Adrenoceptor alpha 2B |
| P636 | route of administration | ... | Q285166 (oral administration) | oral administration |
| P769 | significant drug interaction | ... | Q191521 (sildenafil) | sildenafil |
| P769 | significant drug interaction | ... | Q409468 ((RS)-metoprolol) | (RS)-metoprolol |
| P769 | significant drug interaction | ... | Q410291 (verapamil) | verapamil |
| P769 | significant drug interaction | ... | Q411325 (atenolol) | atenolol |
| P769 | significant drug interaction | ... | Q408556 (levobunolol) | levobunolol |
| P769 | significant drug interaction | ... | Q418857 (acebutolol) | acebutolol |
| P769 | significant drug interaction | ... | Q420586 (celiprolol) | celiprolol |
| P769 | significant drug interaction | ... | Q423364 (propranolol) | propranolol |
| P769 | significant drug interaction | ... | Q424156 (tadalafil) | tadalafil |
| P769 | significant drug interaction | ... | Q424161 (vardenafil) | vardenafil |
| P769 | significant drug interaction | ... | Q424952 (nadolol) | nadolol |
| P769 | significant drug interaction | ... | Q412515 (bisoprolol) | bisoprolol |
| P769 | significant drug interaction | ... | Q412534 (carvedilol) | carvedilol |
| P769 | significant drug interaction | ... | Q794162 (betaxolol) | betaxolol |
| P769 | significant drug interaction | ... | Q958087 (labetalol) | labetalol |
| P769 | significant drug interaction | ... | Q2873270 (avanafil) | avanafil |
| P769 | significant drug interaction | ... | Q413591 (sotalol) | sotalol |
| P769 | significant drug interaction | ... | Q418101 (pindolol) | pindolol |
| P769 | significant drug interaction | ... | Q418130 (nebivolol) | nebivolol |
| P279 | subclass of | ... | Q11173 (chemical compound) | chemical compound |
| P2868 | subject has role | ... | Q575890 (antihypertensive drug) | antihypertensive drug |
| P2868 | subject has role | ... | Q50430371 (adrenergic alpha-1 receptor antagonists) | adrenergic alpha-1 receptor antagonists |
| P2868 | subject has role | ... | Q1927838 (alpha blocker) | alpha blocker |
| P2868 | subject has role | ... | Q4684744 (adrenergic antagonist) | adrenergic antagonist |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | prazosin | ??? |
Why not click here or view trends?
log id: 2856900